RNS Number:6587N
Celsis International PLC
17 July 2003



                            CELSIS INTERNATIONAL PLC



                                 AGM Statement





At today's Annual General Meeting Dr Jack Rowell, Chairman, made the following
statement:



"In the report and accounts for the year ended 31 March 2003, we announced a
major turn around in the performance of the Company and reported a significant
profits increase with solid sales growth.  This was a successful year for Celsis
and we now believe we are in a position to build upon this stable and
sustainable business.



"Celsis' customer base continues to grow, and although we reduced our cost
structure last year, this has not impacted on our ability to provide customers
with superior products and services.  We continue to lead our respective
industries in technology innovation and customer care.



"Our Product Group continues to grow according to plan.  The personal care and
pharmaceutical business sector, which accelerated significantly last year, will
continue to grow as we focus on our GCAM (Global Corporate Account Management)
programme and value-selling approach.  The dairy business will secure more
business as we continue with our strategy of providing superior products at
competitive prices.



"Our Laboratory Group reported increased revenues and profits for the year end
31 March 2003.  Whilst our Laboratory Group has witnessed a slight slowdown in
our pharmaceutical customers research spending in Q1, a number of new customer
focused programmes are currently being implemented to help increase our growth
rate in Q2 and beyond.  This, together with the creation of a dedicated business
development team, leaves us confident that our Laboratory Group will continue to
expand to remain a leading analytical service provider in the US pharmaceutical
industry.



"Since we released our year end results we have seen further progress through a
preferred vendor agreement with GlaxoSmithKline in our Product Group, announced
14 July. Furthermore in our Laboratory Group, Sanofi-Synthelabo, a world leading
pharmaceutical company, has selected Celsis as a preferred provider of
laboratory services in the USA.  Both of these agreements reinforce our
commitment to deliver solid revenue and profit growth according to plan.



"Celsis' strong financial standing means that we are now well positioned for
aggressive growth, both organically and through acquisition opportunities, to
provide increased earnings and shareholder funds."





                                                                    17 July 2003




Enquiries:

Celsis International plc                            Tel: 01638 600 151
Jay LeCoque, Chief Executive Officer
Jenny Parsons, Corporate Communications

College Hill                                        Tel: 020 7457 2020
Nicholas Nelson / Corinna Dorward









Notes to editors



Celsis International plc

Celsis International plc is a world leader in the development and supply of
rapid diagnostic and monitoring systems to detect and measure microbial
contamination in finished products bound for consumers.  It has successfully
developed tests for use in the pharmaceutical, cosmetic and toiletries, food and
beverage industries and is associated with some of the best-known high street
brands in these consumer areas.



These tests are based upon the years of research in enzyme technology that
employ numerous methods for the rapid detection of microbial contamination.  The
result is that microbial testing times are reduced from around five days to a
little over one day, thus lending significant cost advantages to Celsis'
customers.



Celsis International plc also has a leading cGMP laboratory services, supporting
the R&D and manufacturing based testing needs of the pharmaceutical,
biotechnology and personal care industries.  This business unit currently
operates primarily in the United States.



For more information on Celsis International plc go to www.celsis.com




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGMSFAFSWSDSELW